Jiage Ding

Xuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

LGALS9 blockade augments vaccine-induced immune responses against prostate cancer.

LGALS9 blockade augments vaccine-induced immune responses against prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: April 20, 2026

Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.

Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.

Journal: Journal for immunotherapy of cancer

Published: November 28, 2024

Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma.

Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma.

Journal: International journal of biological macromolecules

Published: September 22, 2024

Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors.

Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors.

Journal: Journal for immunotherapy of cancer

Published: August 12, 2024

Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity.

Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity.

Journal: International immunopharmacology

Published: July 09, 2024

Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors.

Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors.

Journal: International immunopharmacology

Published: June 12, 2023

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma.

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma.

Journal: iScience

Published: October 12, 2022

The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.

The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.

Journal: NPJ vaccines

Published: September 21, 2022

Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8+ T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8+ T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Journal: Cancers

Published: July 10, 2022

The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants.

The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: April 28, 2022

IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy.

IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy.

Journal: Cancers

Published: March 15, 2022

Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity.

Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity.

Journal: Pharmacological research

Published: October 08, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026